[HTML][HTML] Experience with a novel efalizumab‐based immunosuppressive regimen to facilitate single donor islet cell transplantation
NA Turgeon, JG Avila, JA Cano, JJ Hutchinson… - American journal of …, 2010 - Elsevier
Islet transplantation is an experimental therapy for selected patients with type 1 diabetes
(T1DM). It remains limited by immunosuppressive drug toxicity, progressive loss of insulin
independence, allosensitization and the need for multiple islet donors. We describe our
experience with an efalizumab‐based immunosuppressive regimen as compared to the
prevailing standard regimen, the Edmonton protocol. Twelve patients with T1DM received
islet transplants: eight were treated with the Edmonton protocol; four were treated with …
(T1DM). It remains limited by immunosuppressive drug toxicity, progressive loss of insulin
independence, allosensitization and the need for multiple islet donors. We describe our
experience with an efalizumab‐based immunosuppressive regimen as compared to the
prevailing standard regimen, the Edmonton protocol. Twelve patients with T1DM received
islet transplants: eight were treated with the Edmonton protocol; four were treated with …
